FDA Opioid Rulings Slammed

March 10, 2014 10:41 PM

26 0

FDA Opioid Rulings Slammed

FDA decisions about prescription opioid painkillers have been inconsistent, and the agency should make future decisions with greater transparency, according to drug safety researchers.

While all extended-release oxycodone products (OxyContin and generics) are required to have abuse-deterrent properties, that's not the case for long-acting oxymorphone (Opana and generics) or hydrocodone (Zohydro), according to Lewis Nelson, MD, of NYU School of Medicine, and colleagues.

Read more

To category page